Research progress of LincRNA-p21 in tumors
10.3760/cma.j.issn.1673-4181.2019.05.011
- VernacularTitle: LincRNA-p21在肿瘤中的研究进展
- Author:
Jing WU
1
;
Deguan LI
Author Information
1. Institute of Radiation Medicine, Chinese Academy of Medical Science & Peking Union Medical College; Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Tianjin 300192, China
- Publication Type:Review
- Keywords:
Non-coding RNA;
Long intergenic non-coding RNA;
LncRNA-p21;
Tumor
- From:
International Journal of Biomedical Engineering
2019;42(5):419-424
- CountryChina
- Language:Chinese
-
Abstract:
Long-chain non-coding RNA (LncRNA) has more than 200 nucleotides in length and cannot encode proteins. It has a variety of biological functions. A large number of studies have shown that LncRNA is closely related to the occurrence and development of cancer. Researches at the level of molecular biology have found that LncRNA acts as an important regulatory molecule involved in the whole process of life activities and plays a regulatory role in various diseases and tumors. LincRNA-p21 is a novel LncRNA that acts as a translational inhibitor by targeting mRNA or by directing the chromatin site of a protein-binding partner. LincRNA-p21 is closely related to a variety of tumors and exerts its biological functions of carcinogenesis or tumor suppression through different pathways. In this paper, the research progress of the tumor-associated gene LincRNA-p21 was reviews
